Brokerages Set Oculis Holding AG (NASDAQ:OCS) Target Price at $43.86

Oculis Holding AG (NASDAQ:OCS) has been given a consensus recommendation of “Moderate Buy” by the eight research firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $43.8571.

A number of research analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $44.00 price objective on shares of Oculis in a report on Monday. Needham & Company LLC increased their price objective on Oculis from $36.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Wall Street Zen downgraded Oculis from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a report on Tuesday. Finally, Stifel Nicolaus increased their price objective on Oculis from $40.00 to $50.00 and gave the company a “buy” rating in a report on Wednesday, March 4th.

Oculis Trading Down 3.9%

OCS opened at $26.77 on Tuesday. Oculis has a one year low of $16.00 and a one year high of $30.68. The company has a market cap of $1.55 billion, a P/E ratio of -11.79 and a beta of 0.48. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.96 and a current ratio of 5.96. The business’s 50-day simple moving average is $27.21 and its 200-day simple moving average is $23.74.

Oculis (NASDAQ:OCS) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.08). Oculis had a negative net margin of 8,173.41% and a negative return on equity of 62.12%. The business had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $0.14 million. As a group, equities research analysts expect that Oculis will post -2.17 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Aberdeen Group plc grew its stake in Oculis by 39.4% during the 4th quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock worth $34,887,000 after buying an additional 493,827 shares during the last quarter. Syquant Capital Sas purchased a new position in Oculis during the 4th quarter worth approximately $3,849,000. Compagnie Lombard Odier SCmA grew its stake in Oculis by 10.6% during the 4th quarter. Compagnie Lombard Odier SCmA now owns 107,300 shares of the company’s stock worth $2,143,000 after buying an additional 10,300 shares during the last quarter. Aventura Private Wealth LLC purchased a new position in Oculis during the 4th quarter worth approximately $80,000. Finally, NEXTBio Capital Management LP purchased a new position in Oculis during the 4th quarter worth approximately $2,991,000. Hedge funds and other institutional investors own 22.30% of the company’s stock.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.